Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


German doctors approve reimbursement catalogue:

This article was originally published in Clinica

Executive Summary

Proposals for the new German reimbursement catalogue for the office-based doctors sector has gained the universal approval of doctors associations around the country. The catalogue, known as the EBM 2000plus, was presented last week in Berlin by the federal association of statutory health insurance physicians. It must now be put before the evaluation committee of the federal committee of doctors and sickness funds in two months time. The difficulty, said the KBV's principal chairman, Manfred Richter-Reichhelm, will be to get the backing of the sickness funds. "If we cannot agree at the evaluation committee stage, then we will not shy away from further debate at the extended evaluation committee stage," he said. The EBM 2000plus should be in place either by October 1 2003, or January 1 2004 if an early agreement cannot be made.

You may also be interested in...

Lannett Plans Seven Launches In Fiscal Year 2021

Lannett will launch a further seven products in fiscal 2021, after launching four products recently in the first quarter of FY21. The company also plans to pay off its Term Loan ‘A’ in full, by the end of November 2020. 

Pfizer Picks Up EU Pegfilgrastim Approval

Pfizer has now received a formal European Commission approval for its Nyvepria biosimilar pegfilgrastim. The approval puts the firm in direct competition with several other versions of the Neulasta original.

A Stroke Of Luck Boosts Oxford/AZ’s “Vaccine For The World”

AstraZeneca's research head admits that the half dose approach was a lucky mistake – but one that could boost the vaccine's effectiveness and supplies. The US regulator may not be persuaded, however.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts